지혈제 시장 규모, 점유율, 성장 분석 : 유형별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Hemostatic Agents Market size was valued at USD 8.03 Billion in 2024 and is poised to grow from USD 8.74 Billion in 2025 to USD 17.15 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

The demand for advanced hemostatic agents is rising due to an increasing prevalence of bleeding disorders and chronic diseases among the aging population. The expansion of surgical procedures globally further drives this market, necessitating effective hemostatic solutions. Additionally, the high incidence of severe bleeding from road accidents contributes to the urgency for these agents. Innovations in surgical techniques, including robotic-assisted procedures, are expected to bolster this demand. However, market growth may face challenges, such as the high costs associated with surgical treatments and unfavorable reimbursement policies. Moreover, limited awareness and understanding of the latest technological advancements in hemostatic agents in emerging and developing countries could hinder overall market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostatic Agents Market Segments Analysis

Global Hemostatic Agents Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Fibrin Sealants and Others. Based on Treatment, the market is segmented into Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery and Others. Based on End User, the market is segmented into Hospitals, Surgery Centers, Nursing Homes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemostatic Agents Market

The increasing volume of surgical procedures worldwide has significantly contributed to the heightened prevalence of bleeding complications during operations, serving as a primary catalyst for the global Hemostatic Agents market. Presently, there is an extensive array of advanced medical devices designed to facilitate hemostasis in surgical settings. Estimates indicate that a substantial proportion of transfused red blood cells are utilized specifically in surgical contexts, underscoring the critical nature of managing bleeding during these interventions. This reality has led to a robust demand for hemostatic products, as many surgeons opt for these solutions to minimize the risks associated with bleeding during surgeries, thus driving market growth.

Restraints in the Global Hemostatic Agents Market

The Global Hemostatic Agents market faces significant restraints due to various clinical limitations that hamper the widespread adoption of these treatments. Uncontrolled bleeding remains a critical concern, restricting the effectiveness of hemostatic agents in certain situations. Although these products provide improved outcomes in managing bleeding during surgical procedures and mitigate infection risks, their high costs pose barriers to accessibility. Furthermore, specific surgical instruments are often required for particular procedures, which can also limit the applications of hemostatic agents. Despite advancements in technology, these clinical constraints continue to constrain the utilization of these crucial products within the medical field.

Market Trends of the Global Hemostatic Agents Market

The Global Hemostatic Agents market is experiencing significant growth driven by the urgent need to address uncontrolled hemorrhage, a leading cause of mortality in both military and civilian settings. As more than 30% of traumatic deaths are attributed to excessive bleeding, the demand for effective hemostatic drugs in emergency and surgical environments is surging. These agents play a vital role in trauma care, mitigating complications such as hypothermia, infections, organ failure, and acidosis, thus enhancing patient survival rates. As awareness of their life-saving potential increases and advancements in hemostatic technology continue, the market is poised for robust expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostatic Agents Market Size by Type & CAGR (2026-2033)

• Market Overview
• Thrombin Based Hemostats
• Gelatin Based Hemostats
• Collagen Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Global Hemostatic Agents Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Cardiovascular
• General Surgery
• Digestive Surgery
• Neurosurgery
• Others

Global Hemostatic Agents Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Global Hemostatic Agents Market Size & CAGR (2026-2033)

• North America (Type, Treatment, End User)
  • US
  • Canada
• Europe (Type, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Medicines Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations